Your doctor doesn't need to read your full medical history to know whether you're healthy. A blood panel tells her in seconds. High cholesterol, low iron, liver function — each number maps to a dimension of health. The pattern across all of them tells the story.
So why do investors still read 30-page pitch decks to figure out whether a startup is healthy?
Five seconds, two stories
Below are two real startups, assessed using the same methodology — the same sixteen value growth dimensions, the same five-level evidence scale, the same valuation engine. The names have been anonymised. The shapes have not.
Company A fills the map. Strong fundamentals across most dimensions, with two specific dips — monetisation and customer acquisition. An investor sees a healthy startup with a clear, solvable problem. The shape tells you where to focus before you read a single word of the report.
Company B collapses inward. Only two or three dimensions reach outward. Everything else is constrained. No single intervention fixes this. An investor sees systemic issues — and either passes quickly or, if turnaround is their speciality, sees precisely where to intervene.
Both readings take five seconds. Nothing else on the market does this.
Growth is the ultimate health indicator
Growth and health have always been intimately linked. In medicine, growth is one of the first things a paediatrician checks — not because growth itself is the goal, but because it is the most reliable signal that everything underneath is working. When the underlying systems are healthy, growth follows. When something is constrained, growth stalls.
Startups work the same way. A startup that is healthy across its value dimensions — strong customer definition, validated pain, clear competitive advantage, capable team, viable monetisation — will grow. A startup that is constrained across multiple dimensions will not, regardless of how much capital you pour into it. The constraint line on the Value Growth Map shows you exactly where growth is being held back.
Two types of investor, one diagnostic
The health diagnostic serves two very different investor motivations — and both are valid.
The first type of investor wants healthy deal flow. They want to find startups that are already strong across most dimensions and need capital to accelerate. For them, the Value Growth Map is a filter. A full, expanded shape means: this one is worth the deeper look. A collapsed shape means: pass quickly and move on.
The second type of investor specialises in turnaround. They look at a constrained Value Growth Map and see opportunity, not risk. An operational VC, an accelerator with a specific methodology, a turnaround fund — they know how to treat specific conditions. For them, the map is not a filter but a treatment plan. The constrained dimensions are precisely where they add value.
Both readings come from the same diagnostic. The map doesn't tell the investor what to do — it gives them the information to make that judgment in seconds instead of weeks.
What a pitch deck cannot show you
A pitch deck is a narrative. It is designed to persuade. The information it contains is selected by the founder to present the strongest possible case. That is not dishonest — it is what selling looks like. But it means the pitch deck systematically omits the dimensions where the startup is weak.
The Value Growth Map cannot omit anything. All sixteen dimensions are always visible. A strong dimension shows as a point reaching outward. A weak dimension shows as a collapse inward. The shape is the shape — it cannot be polished, designed, or rehearsed.
That is what makes it a diagnostic rather than a presentation. A blood panel doesn't care whether the patient wants to look healthy. It measures what is actually there.
"The startups worth backing don't always look like it. The ones that do aren't always worth it."
Before the first call
The traditional due diligence process takes weeks. An analyst reads the deck, researches the market, talks to the founders, builds the evidence picture. Most of that is desk work — and most investors cannot afford to do it for every startup that crosses their desk. So they rely on pattern recognition, gut feel, and a thirty-minute call. Some good deals slip through. Everyone knows this.
The Value Growth Map changes when the diagnostic happens. Not after the second partner meeting. Not after two weeks of analyst effort. Before the first call. An investor who can see the health of a startup in five seconds can make better decisions about where to invest their time — and their capital.
That is what a startup health diagnostic does. It makes the condition visible, so the right decision can be made at the right time.